Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same
US11447559B2 · kind B2 · utility
1Cited by
0References
27Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 21, 2018 |
| Grant date | Sep 20, 2022 |
| Priority date | — |
| Expiry date | Sep 21, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided according to an embodiment of the present invention is an antibody that binds specifically to B-cell maturation antigen (BCMA) and comprises a heavy chain variable domain (VH domain) composed of a sequence having a homology of 80% or higher with any one of the amino acid sequences of SEQ ID NOS: 1 to 20, or a fragment thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.